FORTITUDE Canadian Trademark Information
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disordersConducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing medical and scientific research information in the fields of...
Perfect for these industries
Words that describe this mark
oligonucleotideconjugate based therapies oligonucleotideantibody conjugate based therapies oligonucleotideantibody fragment conjugate based therapies treatment viral metabolic endocrine musculoskeletal cardiovascular cardiopulmonary neuromuscular rare muscle diseases cardiomyopathies heart muscle
On Thursday, March 30, 2023, a canadian trademark registration was filed for
FORTITUDE by Avidity Biosciences, Inc. *********, **********, ***** ****.
The Canadian IP office has given the trademark application number of
2249157.
The current status of this trademark filing is Filing date accorded.
The FORTITUDE
trademark is filed in the description of
Oligonucleotide-conjugate based therapies, oligonucleotide-antibody conjugate based therapies, and oligonucleotide-antibody fragment conjugate based therapies for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
,
Conducting clinical trials in the fields of pharmaceuticals and biotechnology, namely, conducting clinical trials for the for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, neuromuscular, rare muscle diseases, cardiomyopathies, heart muscle diseases, muscular dystrophies, muscle atrophy, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; medical and scientific research, namely, conducting clinical trials for oligonucleotide-based therapeutics; conducting clinical trials; providing medical and scientific research information in the field of clinical trials; pharmaceutical research and development; research and development in the medical biotechnology field
.
100% Satisfaction Guarantee
protect your valuable brand now.
Classification Information